TARGET KRAS WITH CONFIDENCE
KRASmut PDO SCREEN
Test the efficacy of your compound(s) in a panel of 25 patient-derived organoids representing colorectal, lung, and pancreatic cancer
Colorectal
cancer
Lung
cancer
Pancreatic
cancer
Proven Impact
Our meticulously designed KRASmut panel was instrumental in developing the first-ever clinical candidate using organoid technology, targeting head & neck cancer
Panel features
- Largest commercially available KRASmut PDO panel including 25 models
- Representing pivotal KRAS mutants such as G12A, G12D, G12V, G13D and many others
- Rigorously characterized, with readily available RNA or DNA sequencing data
- Diverse models encompassing both primary and metastatic tumors
- Test off-tumor toxicities with matched normal organoids
- The most competitive pricing on the market when choosing a full panel screen
Advanced screening capabilities
- Direct measurement of cell viability with an image-based viability readout
- High-throughput 3D assay format
- Test as many compound(s) as you want
- No minimum number of models to enroll
- High-data quality with 10-point dose-response curves per compound
- Inclusive of IC50 determination and IC50 heatmap generation
Screen Schedule 2025
| Enrollment deadline | Compound receival deadline | Data delivery |
|---|---|---|
|
1st April
 |
28th April | 9th June |
|
16th May
 |
15th June | 28th July |
| 28th July | 22nd August | 6th October |
| 29th September | 24th October | 8th December |
Test your compound on our adagrasib resistant PDO for free
Valid for any study of more than 4 PDOs
Accelerate your KRAS drug development with our comprehensive portfolio
Identify promising leads
Benchmark against standard of care
Understand the mechanism of action
Investigate resistance mechanisms
Craft optimal combination
therapy
therapy
Develop co-clinical
biomarker assays
biomarker assays
Companion
diagnostics partnering
diagnostics partnering